ENTITY
Bristol-Myers Squibb

Bristol-Myers Squibb (BMY UN)

2
Analysis
Health CareUnited States
Bristol-Myers Squibb Company is a global biopharmaceutical company. The Company develops, licenses, manufactures, markets, and sells pharmaceutical and nutritional products. Bristol Myers Squibb focuses on products and experimental therapies address cancer, heart disease, HIV and AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection, and psychiatric disorders.
more
30 Jan 2017 13:50

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

AML represents one of the largest hematologic cancer populations with one of the worst survival rates. Global prevalence is expected to increase at...

15 Jan 2017 19:34

Cybercriminals and Activists Scale up Their Attacks – Who's at Risk and Why?

Distributed denial of service (DDoS) attacks have significantly increased in size, carried out by threat actors exploiting internet of things (IoT)...

Logo
316 Views
Share
19 Dec 2016 23:09

2017 Asset Allocation Outlook – Part 2: Trump Reflation Euphoria to Fade?

The overwhelming investor consensus a year ago was for further EM/commodity downside amid deflation fears - this year it is a USD secular bull and...

Logo
322 Views
Share
13 Dec 2016 11:44

American Society of Hematology- (ASH) Annual Conference (2016) Review

We reviewed data presented at the American Society of Hematology (ASH) conference in San Diego last week with a focus on the evolving treatment...

07 Dec 2016 19:48

Ono Pharmaceutical: Time to Accumulate

New entry into our Asia Pacific Model Portfolio at 4.54% weight: We added Ono Pharmaceutical Co Ltd (4528 JP) to our Asia Pacific Model Portfolio...

Logo
341 Views
Share
x